AstraZeneca Yönetim

Yönetim kriter kontrolleri 3/4

AstraZeneca CEO'su Pascal Soriot, Oct2012 tarihinde atandı, in görev süresi 12.08 yıldır. in toplam yıllık tazminatı $ 21.48M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.5% maaş ve 91.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.014% ine doğrudan sahiptir ve bu hisseler € 27.78M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 9.4 yıl ve 7 yıldır.

Anahtar bilgiler

Pascal Soriot

İcra Kurulu Başkanı

US$21.5m

Toplam tazminat

CEO maaş yüzdesi	8.5%
CEO görev süresi	12.1yrs
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	9.4yrs
Yönetim Kurulu ortalama görev süresi	7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Pascal Soriot'un ücretlendirmesi AstraZeneca'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$6b
Jun 30 2024	n/a	n/a	US$6b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$21m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$5b
Dec 31 2022	US$18m	US$2m	US$3b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	-US$1b
Mar 31 2022	n/a	n/a	-US$1b
Dec 31 2021	US$21m	US$2m	US$112m
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$22m	US$2m	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$20m	US$2m	US$1b
Sep 30 2019	n/a	n/a	US$2b
Jun 30 2019	n/a	n/a	US$2b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$16m	US$2m	US$2b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$3b
Mar 31 2018	n/a	n/a	US$3b
Dec 31 2017	US$14m	US$2m	US$3b

Tazminat ve Piyasa: Pascal 'nin toplam tazminatı ($USD 21.48M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 4.78M ).

Tazminat ve Kazançlar: Pascal 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Pascal Soriot (65 yo)

12.1yrs

Görev süresi

US$21,484,390

Tazminat

Mr. Pascal Soriot, M.B.A., D.V.M., has been the Chief Executive Officer and Executive Director at AstraZeneca PLC since October 1, 2012. He served as Director at Acerta Pharma B.V. He had been Independent...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Pascal Soriot	CEO & Executive Director	12.1yrs	US$21.48m	0.014% € 27.8m
Aradhana Sarin	CFO & Executive Director	3.3yrs	US$5.62m	0.0053% € 10.3m
Pam Cheng	EVP of Global opt. & IT	9.4yrs	Veri yok	Veri yok
Andrew Barnett	Head of Investor Relations	no data	Veri yok	Veri yok
Jeffrey Pott	CHRO, Chief Compliance Officer	15.8yrs	Veri yok	Veri yok
Gonzalo Vina	Head of Global Media Relations	no data	Veri yok	Veri yok
Ruud Dobber	Executive Vice-President of BioPharmaceuticals Business Unit	11.8yrs	Veri yok	Veri yok
Susan Galbraith	Executive Vice President of Oncology Research & Development	no data	Veri yok	Veri yok
Leon Wang	Executive VP of International & China President	10.8yrs	Veri yok	Veri yok
Iskra Reic	Executive Vice-President of Vaccines & Immune Therapies	7.6yrs	Veri yok	Veri yok
David Fredrickson	Executive Vice-President of Oncology Business Unit	7.1yrs	Veri yok	Veri yok
Ruth March	Senior VP of Precision Medicine - R&D Oncology	5.8yrs	Veri yok	Veri yok

9.4yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: ZEG 'un yönetim ekibi deneyimli ve deneyimlidir ( 9.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Pascal Soriot	CEO & Executive Director	12.1yrs	US$21.48m	0.014% € 27.8m
Aradhana Sarin	CFO & Executive Director	3.3yrs	US$5.62m	0.0053% € 10.3m
Pam Cheng	EVP of Global opt. & IT	no data	Veri yok	Veri yok
Jeffrey Pott	CHRO, Chief Compliance Officer	no data	Veri yok	Veri yok
Marcus Wallenberg	Non-Executive Director	25.6yrs	US$159.35k	0.0039% € 7.5m
Philip John Broadley	Senior Independent Non-Executive Director	7.6yrs	US$254.96k	0.00052% € 1.0m
Michel Demare	Independent Chairman	5.2yrs	US$744.49k	0.00065% € 1.3m
Deborah DiSanzo Eldracher	Independent Non-Executive Director	6.9yrs	US$152.98k	0.000060% € 116.7k
Sherilyn S. McCoy	Independent Non-Executive Director	7.1yrs	US$223.09k	0.00011% € 214.0k
Euan Ashley	Independent Non-Executive Director	4.1yrs	US$151.70k	0.000070% € 136.2k
Shu Kam Mok	Independent Non-Executive Director	5.8yrs	US$140.23k	0.00013% € 252.9k
Nazneen Rahman	Independent Non-Executive Director	7.4yrs	US$203.97k	0.000070% € 136.2k

7.0yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ZEG 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7 yıldır).

AstraZeneca Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

CEO & Executive Director recently bought €2.5m worth of stock

Recent updates

CEO & Executive Director recently bought €2.5m worth of stock

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Third quarter 2024 earnings released: EPS: US$0.92 (vs US$0.89 in 3Q 2023)

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca plc Announces Astrazeneca and Ionis' Wainzua (Eplontersen) Recommendation for Approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

Astrazeneca’S CALQUENCE® (acalabrutinib) Receives Priority Review in the US for Patients with Untreated Mantle Cell Lymphoma

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Cas Datifan in Combination with Volrustomig in Renal Cell Carcinoma

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Astrazeneca PLC Tagrisso Receives US Approval in Unresectable Stage III EGFR-Mutated Lung Cancer Lung Cancer

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

AstraZeneca PLC’s FluMist Receives Approval for Self-Administration in the US

AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca Announces Positive Results from the Niagara Phase III Trial

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Astrazeneca Presents Interim Results from the Randomized NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Present At the WCLC 2024

Astrazeneca's Imfinzi Receives Approval in US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery

Astrazeneca's Supplemental Biologics License Application for Imfinzi (Durvalumab) Granted Priority Review and Breakthrough Therapy Designation for Patients with Limited-Stage Small Cell Lung Cancer in the US

Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial

First half dividend of UK£0.78 announced

FDA Advisory Committee Reviewes Astrazeneca's Imfinzi for Treatment of Resectable Non-Small Cell Lung Cancer Based on Aegean Phase III Trial Results

Second quarter 2024 earnings released: EPS: US$1.24 (vs US$1.17 in 2Q 2023)

Astrazeneca plc Announces Voydeya Approved in Canada as Add-On Therapy to Ravulizumab or Eculizumab for Adults with the Rare Disease PNH Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş